Achieving no evidence of disease activity-3 in highly active multiple sclerosis patients treated with cladribine and monoclonal antibodies

Achieving no evidence of disease activity-3 in highly active multiple sclerosis patients treated with cladribine and monoclonal antibodies

Background We aimed to determine the proportion of highly active multiple sclerosis patients under high-efficacy therapies (HETs) achieve no evidence of disease activity-3 (NEDA-3) at 1 and 2 years, and to identify factors associated with failing to meet no evidence of disease activity 3 at 2 years....

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Multiple sclerosis journal - experimental, translational and clinical translational and clinical, 2023-01, Vol.9 (1), p.20552173231154712-20552173231154712
Hauptverfasser: Alonso, Ricardo, Casas, Magdalena, Lazaro, Luciana, Fernandez Liguori, Nora, Pita, Cecilia, Cohen, Leila, Rojas, Juan Ignacio, Pappolla, Agustín, Patrucco, Liliana, Cristiano, Edgardo, Burgos, Marcos, Vrech, Carlos, Piedrabuena, Raul, Pablo, Lopez, Deri, Norma, Luetic, Geraldine, Miguez, Jimena, Cabrera, Mariela, Martinez, Alejandra, Zanga, Gisela, Tkachuk, Verónica, Tizio, Santiago, Carnero Contentti, Edgar, Knorre, Eduardo, Leguizamon, Felisa, Mainella, Carolina, Nofal, Pedro, Liwacki, Susana, Hryb, Javier, Menichini, Maria, Pestchanker, Claudia, Alonso, Marina, Garcea, Orlando, Silva, Berenice
Format: Artikel
Sprache:eng
Schlagworte:
Confidence intervals
Multiple sclerosis
Original
Patients
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background We aimed to determine the proportion of highly active multiple sclerosis patients under high-efficacy therapies (HETs) achieve no evidence of disease activity-3 (NEDA-3) at 1 and 2 years, and to identify factors associated with failing to meet no evidence of disease activity 3 at 2 years. Methods This retrospective cohort study based on Argentina Multiple Sclerosis patient registry (RelevarEM), includes highly active multiple sclerosis patients who received HETs. Results In total, 254 (78.51%) achieved NEDA-3 at year 1 and 220 (68.12%) achieved NEDA-3 at year 2. Patients who achieved NEDA-3 at 2 years had a shorter duration of multiple sclerosis (p 
ISSN:2055-2173
2055-2173
DOI:10.1177/20552173231154712